For the Inventor, By the Inventor

Enter inventor name

San Diego, CA, United States of America

Sui Xiong Cai

USPTO Granted Patents = 87 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 24

Forward Citations = 1,590(Granted Patents)

Forward Citations (Not Self Cited) = 1,508(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Eugene, OR (US) (1996)
Foothill Ranch, CA (US) (1998 - 1999)
Irvine, CA (US) (1995 - 2001)
Foothill, CA (US) (2000 - 2003)
San Diego, CA (US) (2000 - 2013)

Company Filing History:

State of Oregon

Euro-celtique S.a.

4. 9 out of 15,502

University of California

Acea Pharmaceuticals, Inc.

Purdue Neuroscience Company

8. 3 out of 2,538

Warner-lambert Company

10. 3 out of 16

Shire Biochem, Inc.

Myriad Pharmaceuticals, Inc.

Epicept Corporation

13. 1 out of 139

University of Oregon

14. 5 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2013

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Caspase Activators

Apoptosis Inducers

Pharmaceutical Compounds

Fluorescent Reporter Molecules

Protease Inhibitors

Oxadiazoles

Chromenes

Aminoacetamides

Thiosemicarbazones

Gambogic Acid Derivatives

Coumarins

Quinazolines

87 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8426431 - Substituted 2-aminoacetamides and the use thereof (2013-04-23),

2. 8258145 - Method of treating brain cancer (2012-09-04),

3. 7989462 - 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2011-08-02),

4. 7968595 - Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof (2011-06-28),

5. 7872127 - Substituted 2-aminoacetamides and the use thereof (2011-01-18),

6. 7842805 - Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof (2010-11-30),

7. 7732468 - [object Object] (2010-06-08),

8. 7652006 - Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof (2010-01-26),

9. 7622497 - Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis (2009-11-24),

10. 7618975 - 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-11-17),

11. 7592143 - Methods of treating diseases responsive to induction of apoptosis and screening assays (2009-09-22),

12. 7541465 - Substituted 2-aminoacetamides and the use thereof (2009-06-02),

13. 7528164 - Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-05-05),

14. 7507762 - [object Object] (2009-03-24),

15. 7504382 - Protease inhibitors for coronaviruses and SARS-CoV and the use thereof (2009-03-17),

Title: The Innovative Work of Inventor Sui Xiong Cai

Introduction: Inventor Sui Xiong Cai, based in San Diego, CA, is a prolific innovator with a remarkable portfolio of 73 patents. His groundbreaking research has led to significant advancements in pharmaceuticals and the treatment of various medical conditions.

Latest Patents: Among his latest patents is the invention of substituted 2-aminoacetamides for the treatment of neuronal damage following ischemia and other conditions such as pain, anxiety, and manic depression. Additionally, his method for treating brain cancer using 4-arylamino-quinazolines shows promise in addressing abnormal cell growth and spread, particularly in the case of brain cancer.

Career Highlights: Sui Xiong Cai has made significant contributions to the field of pharmaceuticals through his work at companies such as Cytovia, Inc. and Euro-Celtique S.A. His expertise and dedication to innovation have been instrumental in developing novel treatment options for a range of clinical conditions.

Collaborations: Throughout his career, Sui Xiong Cai has collaborated with esteemed colleagues such as John A. Drewe and Han-Zhong Zhang. These collaborations have fostered creativity and synergy, leading to the successful development of groundbreaking technologies and treatment methods.

Conclusion: In summary, Sui Xiong Cai's inventive spirit and dedication to advancing medical science have positioned him as a leading figure in the field of pharmaceutical innovation. His work continues to inspire and pave the way for future breakthroughs in the treatment of various medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…